Can Infliximab Be Combined with Azathioprine for Fistulizing Crohn's Disease?
Yes, infliximab should be combined with azathioprine (or other thiopurines) for fistulizing Crohn's disease, particularly in patients who are biologic-naive and immunomodulator-naive. This combination approach is supported by current guidelines and demonstrates superior outcomes compared to monotherapy.
Guideline-Based Recommendations
The 2025 AGA guidelines suggest using infliximab in combination with thiopurines (including azathioprine) rather than infliximab monotherapy in adult patients with moderate-to-severe Crohn's disease who are naïve to both biologics and immunomodulators 1. While this recommendation is conditional with low certainty evidence, it applies to the broader population of Crohn's disease patients, which includes those with fistulizing disease.
For fistulizing disease specifically, the 2021 AGA guidelines strongly recommend infliximab for induction and maintenance of fistula remission 2. The FDA label confirms infliximab's efficacy in fistulizing Crohn's disease, noting that concurrent use of stable doses of azathioprine (AZA) was permitted in pivotal trials 3.
Evidence Supporting Combination Therapy
The landmark SONIC trial demonstrated that combination therapy with infliximab plus azathioprine achieved superior outcomes compared to either agent alone 4. In this study of 508 patients with moderate-to-severe Crohn's disease:
- 56.8% of combination therapy patients achieved corticosteroid-free remission at week 26 versus 44.4% with infliximab alone (P=0.02) and 30.0% with azathioprine alone (P<0.001)
- Mucosal healing occurred in 43.9% with combination therapy versus 30.1% with infliximab alone (P=0.06)
For fistulizing disease specifically, a pilot study showed that combining infliximab with long-term 6-mercaptopurine/azathioprine resulted in complete fistula closure in 75% of patients that persisted for >6 months (median follow-up 10 months), with median time to closure of 14 days 5. This suggests the combination prolongs the effect of infliximab on fistula closure.
Real-world data from Canadian provinces involving 11,244 patients on anti-TNF therapy demonstrated that combination therapy was associated with significantly decreased treatment failure for both Crohn's disease (adjusted HR 0.77,95% CI 0.66-0.90) and ulcerative colitis 6.
Practical Implementation
Dosing:
- Infliximab: 5 mg/kg at weeks 0,2, and 6, then every 8 weeks 3
- Azathioprine: 2-2.5 mg/kg/day (adjust for drug metabolism) 1
Key Considerations:
- The benefit is most established in biologic-naive and immunomodulator-naive patients 1
- Combination therapy may be particularly valuable in patients at higher risk for immunogenicity, including those with history of anti-drug antibodies, re-exposure after prolonged lapse, HLA-DQ-A1*05 variants, or high drug clearance states 1
- For patients who previously failed immunomodulator monotherapy, the benefit of adding it back with infliximab is uncertain 1
Safety Profile
The safety profile is acceptable. In the SONIC trial, serious infections occurred in 3.9% of combination therapy patients versus 4.9% with infliximab alone and 5.6% with azathioprine alone 4. However, critical warning: hepatosplenic T-cell lymphoma (HSTCL), though rare, has been reported almost exclusively in patients receiving azathioprine or 6-mercaptopurine concomitantly with TNF-blockers, particularly in adolescent or young adult males with Crohn's disease 3.
De-escalation Strategy
Once patients achieve corticosteroid-free clinical remission for at least 6 months on combination therapy, the 2025 AGA guidelines suggest withdrawing the immunomodulator (azathioprine) rather than continuing combination therapy 1. This approach balances efficacy with long-term safety concerns, particularly regarding malignancy risk.
Clinical Algorithm
- Start combination therapy (infliximab + azathioprine) in biologic-naive, immunomodulator-naive patients with fistulizing Crohn's disease
- Monitor response at weeks 2,6, and 14 with clinical assessment of fistula drainage
- Continue maintenance with both agents through at least 6 months of remission
- Consider withdrawing azathioprine after sustained remission (≥6 months) to minimize long-term immunosuppression risks
- Continue infliximab maintenance every 8 weeks indefinitely for fistula control
This approach maximizes initial response rates while allowing for eventual de-escalation to minimize long-term complications from dual immunosuppression.